98%
921
2 minutes
20
Objectives: Platelet (PLT) recovery after chemotherapy is associated with the prognosis of patients with acute myeloid leukaemia (AML). This study aimed to explore the prognostic significance of early high PLT values in patients with de novo non-M3 AML who achieved first complete remission (CR).
Methods: A total of 206 patients with de novo non-M3 AML were analysed in this retrospective study. A receiver operating characteristic (ROC) curve was used to determine the optimal PLT cut-off. The overall survival (OS) and relapse-free survival (RFS) were assessed using Kaplan-Meier and Cox regression analyses.
Results: 312×10 /L was confined as the cut-off of the PLT count. The estimated 3-year OS of patients with high PLT was higher than that of their counterparts (72.3% vs. 34.6%, p = 0.001). In subgroup analysis, patients with high PLT had better OS in the favourable- and intermediate-risk (non-adverse-risk) AML (p = 0.001). The estimated 3-year RFS for the high and low PLT groups was 75.1% and 45.7% respectively (p = 0.078). Multivariate analyses revealed that high PLT count was an independent favourable variable for OS (HR = 0.264, p < 0.001) and RFS (HR = 0.375, p = 0.011) in the non-adverse-risk group.
Conclusion: Our results showed that early high PLT count recovery at first CR in non-adverse-risk AML patients is a positive prognostic marker for survival outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841180 | PMC |
http://dx.doi.org/10.1002/jcla.24221 | DOI Listing |
Front Endocrinol (Lausanne)
September 2025
Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Background: Wilson disease (WD), an inherited copper metabolism disorder, is linked to hepatic injury from copper accumulation-induced dyslipidemia. Children with WD have a high incidence of dyslipidemia, yet personalized risk assessment tools are lacking. This study established a predictive nomogram to provide foundational evidence for early detection in this population.
View Article and Find Full Text PDFAnn Med
December 2025
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Background: Thrombocytopenia (TCP) and coagulation disorders are common complications for patients with liver cirrhosis. The impact of severe TCP [30 × 10/L < platelets (PLT) ≤ 50 × 10/L] and coagulation disorder on bleeding risk after Hassab's operation or partial hepatectomy (PH) for cirrhotic patients is unclear.
Method: Our study retrospectively enrolled 724 cirrhotic patients from July 2019 to August 2024, including 189 patients who underwent Hassab's operation and 535 patients with hepatocellular carcinoma who underwent PH without prophylactic platelet transfusions or thrombopoietin receptor agonists.
Thromb Haemost
September 2025
Department of Medicine-Solna, Division of Cardiovascular Medicine, Karolinska Institutet, Stockholm, Sweden.
Background Atherosclerosis involves inflammatory and thrombotic mechanisms, to which platelets, CD4+ T effector cells, and transforming growth factor β (TGFβ) all contribute importantly. Platelets are the principal source of circulating TGFβ, which profoundly regulates CD4+ T effector cell responses. The impact of platelet-derived TGFβ on atherosclerosis is, however, unknown.
View Article and Find Full Text PDFInt J Biol Markers
September 2025
Postgraduate Training Base Alliance, Wenzhou Medical University, China.
BackgroundDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. The aim of this study was to comprehensively analyze the clinical, cytomorphological, and flow cytometry characteristics of DLBCL patients, with a focus on bone marrow involvement (BMI), to identify novel prognostic factors.MethodsThe clinical, cytomorphological, and flow cytometry characteristics of 220 DLBCL patients were collected from January 2017 to April 2024.
View Article and Find Full Text PDFJ Vis Exp
August 2025
Grupo de Investigación DICOVI, Departamento de Diseño, Universidad de Caldas.
Platelet-rich plasma (PRP) is widely utilized as a routine treatment for chronic musculoskeletal conditions in horses, such as osteoarthritis, tendinopathies, and desmopathies. This effectiveness stems from the high concentration of growth factors and anti-inflammatory cytokines that are released upon activation of this orthobiologic agent, whether activated endogenously or exogenously. Despite its growing popularity, there is a notable absence of instructional videos that demonstrate the techniques for obtaining PRP in horses.
View Article and Find Full Text PDF